VIDEO: Gilteritinib plus chemotherapy well tolerated in newly diagnosed AML
Click Here to Manage Email Alerts
Gilteritinib, an oral FMS-like tyrosine kinase 3 inhibitor, plus induction and consolidation chemotherapy showed efficacy in newly diagnosed FLT3-mutated acute myeloid leukemia, according to data presented at ASH Annual Meeting and Exposition.
The composite complete remission rate of gilteritinib (Xospata, Astellas) was about 81% in the FLT3-mutant patient subset, Keith W. Pratz, MD, director of the Leukemia Program at Penn Medicine, told Healio in a video interview. He noted that this is “a reasonably good number” compared with remission rates seen in phase 3 studies with 7+3 midostaurin (Rydapt, Novartis), which are about 60% to 65%.
“The take home message here is that we were able to establish that gilteritinib ... can be safely given with induction and consolidation chemotherapy. We’ve established the dosing and we are now able to proceed with the randomized study 7+3 gilteritinib vs. 7+3 midostaurin,” he said.
Collapse
Pratz KW, et al. Abstract 24. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about
Click Here to Manage Email Alerts